<?xml version="1.0" encoding="UTF-8"?>
<p>Overall, there were few clinical differences between GBS patients with laboratory evidence of recent ZIKV infection and those without. Patients with both laboratory evidence of ZIKV infection and at least one antecedent typical ZIKV symptom (“symptomatic ZIKV”) reported dyspnea more frequently (43% vs 5%, OR: 13.50, 95% CI: 1.10–165.97 (
 <xref rid="pone.0230132.t006" ref-type="table">Table 6</xref>). Hughes score at nadir was not significantly different between ZIKV+ and ZIKV- GBS case-patients (
 <xref rid="pone.0230132.t007" ref-type="table">Table 7</xref>).
</p>
